LAUNXP Biomedical Co., Ltd

LAUNXP Biomedical Co., Ltd is a biotechnology company focused on research and development of drugs for cancer patients. Its pipeline includes preclinical candidates: LXP5948 for non-small cell lung cancer and Alzheimer's disease, LXP5268 for triple negative breast cancer, LXP5101 for pancreatic cancer, LXP1788 for gastrointestinal cancer, and virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan.